AOSEPT (CLEAR CARE) PLUS Study
AOSEPT™ PLUS With HydraGlyde FID 120947A and AOCup Lens Case (CLEAR CARE PLUS) and AOSEPT™ PLUS FID 119056 and AOCup Lens Case (CLEAR CARE) Family PMCF Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Alcon Call Center
- Phone Number: 1-888-451-3937
- Email: alcon.medinfo@alcon.com
Study Locations
-
-
Texas
-
Fort Worth, Texas, United States, 76134
- Contact Alcon Call Center for Trial Locations
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Subject and parent/legally authorized representative able to understand and sign an Institution Review Board approved informed consent/assent form.
- Subject willing to follow and be able to attend all scheduled study visits as required per protocol.
- Successful wear of daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses in both eyes for the past 3 months for a minimum of 5 days per week and 8 hours per day.
- Other protocol-specified inclusion criteria may apply.
Key Exclusion Criteria:
- Any ocular disease or condition that would contraindicate contact lens wear.
- Use of systemic or ocular medication that would contraindicate contact lens wear.
- Any known sensitivity to any ingredients in the study products.
- Current or history of pathological dry eye in either eye that would in the opinion of the Investigator preclude contact lens wear.
- Any use of habitual/prescribed topical ocular medication or artificial tear or rewetting drop (habitual) that would require instillation during the study.
- Other protocol-specified exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AOSEPT Plus (CC)
AOSEPT Plus and AOCup lens case used as instructed with habitual contact lenses for 90 days.
It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
|
Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus) and a lens case (AOCup) with a neutralizer disc.
The solution and lens case must be used together.
Other Names:
Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
|
|
Experimental: AOSEPT Plus with HydraGlyde (CCP)
AOSEPT Plus with HydraGlyde and AOCup lens case used as instructed with habitual contact lenses for 90 days.
It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
|
Daily wear, reusable, soft (including hydrogel and silicone hydrogel) or rigid gas permeable (RGP) contact lenses according to subject's habitual prescription worn in both eyes and removed prior to sleep for cleaning and disinfection with the study product provided.
Commercially available cleaning, disinfecting, and storage system consisting of a hydrogen-peroxide based solution (AOSEPT Plus with HydraGlyde) and a lens case (AOCup) with a neutralizer disc.
The solution and lens case must be used together.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Front surface deposits at Day 90
Time Frame: Day 90
|
Protein and lipid deposits on the front surface of the contact lens will be assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye.
Deposits will be graded on a 5-point scale, with 0 being absent and 4 being severe.
|
Day 90
|
|
Back surface deposits at Day 90
Time Frame: Day 90
|
Protein and lipid deposits on the back surface of the contact lens will be assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye.
Deposits will be graded on a 5-point scale, with 0 being absent and 4 being severe.
|
Day 90
|
|
Incidence of corneal infiltrative events
Time Frame: Up to Day 90
|
A corneal infiltrate is a single or group of inflammatory cells in the normally clear cornea.
Corneal infiltrative events will be detected by the investigator during an eye exam.
|
Up to Day 90
|
|
Incidence of microbial keratitis
Time Frame: Up to Day 90
|
Microbial keratitis is a sight-threatening infection of the cornea.
Incidences of microbial keratitis will be detected by the investigator during an eye exam.
|
Up to Day 90
|
|
Incidence of solution induced corneal staining (SICS)
Time Frame: Up to Day 90
|
Corneal staining determined by the investigator to be solution-related will be graded by type (pattern of staining) and area (how much) in each of the 5 corneal regions: central, superior, nasal, inferior, temporal.
|
Up to Day 90
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trial Lead, Vision Care, Alcon Research, LLC
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- LCT783-P001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.